September 12, 2012
Eli Lilly Japan announced on September 10 that it filed a public knowledge-based application for the anticancer agent Gemzar Injection 200 mg/1 g (gemcitabine) for an additional indication of recurrent or refractory malignant lymphoma on the same day. Malignant lymphoma...read more